Healthcare / Medical DevicesStockholm
$3.60
-0.10 (-2.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-8.2M · quality 73.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$31M
P/E
6.3x
↓EV/EBITDA
2.9x
↓ROE
12.4%
↑Gross Margin
52.2%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.9%
FCF CAGR
—
FCF margin
-56.4%
FCF / Net income
-3.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.6M · net income $2.5M · FCF $-8.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.6M | $14.6M | $6.9M | $9.9M | $10.1M |
| Net Income | $2.5M | $2.5M | $-2.5M | $-18.3M | $-19.2M |
| EBITDA | $4.4M | $4.4M | $-1.8M | $-18.0M | $-18.6M |
| EPS | 0.53 | 0.53 | -0.58 | -6.62 | -27.60 |
| Gross Margin | 52.2% | 52.2% | 45.3% | 58.8% | 65.7% |
| Operating Margin | 14.0% | 14.0% | -35.4% | -186.1% | -188.9% |
| Net Margin | 16.8% | 16.8% | -35.6% | -183.9% | -189.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | — | 0.01 | 0.03 |
| Current Ratio | 2.54 | 2.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.2M | $-8.2M | $-7.1M | $-17.0M | $-20.7M |
| Returns | |||||
| ROE | 12.4% | 12.4% | -31.5% | -226.5% | -136.6% |
| Valuation | |||||
| P/E | 6.32 | 6.32 | — | — | — |
| EV/EBITDA | 2.87 | 2.87 | — | — | — |
| P/B | 0.85 | 0.85 | 2.06 | 0.53 | 2.45 |
| Growth & Yield | |||||
| Revenue Growth | 109.8% | 109.8% | -30.2% | -1.8% | — |
| EPS Growth | 190.4% | 190.4% | 91.2% | 76.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-15.3%
EPS terminal req.
$0.32
Spread vs growth
205.7%
5Y implied EPS CAGR
-6.0%
EPS terminal req.
$0.39
Spread vs growth
196.4%
10Y implied EPS CAGR
1.7%
EPS terminal req.
$0.62
Spread vs growth
188.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.58 → 0.53
Residual
-12.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.